NASDAQ:NLTX
Delisted
Neoleukin Therapeutics Inc Stock News
$3.49
+0 (+0%)
At Close: Mar 15, 2024
Neoleukin Therapeutics Announces Appointment of Donna Cochener as General Counsel
12:00pm, Tuesday, 15'th Mar 2022 Benzinga
SEATTLE, March 15, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ: NLTX ), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Donna M. Cochener as General Counsel, Senior Vice President Legal. Ms. Cochener joins Neoleukin after serving as Senior Vice President, Deputy General Counsel at HomeStreet, Inc., the parent company of HomeStreet Bank. In that role, she was primarily responsible for securities reporting and compliance and corporate governance as well as serving as lead attorney on a range of transactions, including mergers and acquisitions and debt and equity financings. Prior to her position with HomeStreet, Ms. Cochener was a partner at Davis Wright Tremaine, LLP in Seattle, and worked as an associate at the Seattle offices of Heller Ehrman, LLP, Riddell Williams, P.S. and Perkins Coie, LLP. "Donna is a seasoned executive with a wide range of experiences in public company practices and securities and corporate law.
Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual Meeting
09:01pm, Tuesday, 08'th Mar 2022 GlobeNewswire Inc.
SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo�
Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q4 2021 Results - Earnings Call Transcript
08:56pm, Tuesday, 01'st Mar 2022
Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q4 2021 Results - Earnings Call Transcript
Neoleukin Therapeutics Inc Shares Fall 0.8% Below Previous 52-Week Low - Market Mover
03:34am, Friday, 14'th Jan 2022 Kwhen Finance
Neoleukin Therapeutics Inc (NLTX) shares closed 0.8% lower than its previous 52 week low, giving the company a market cap of $158M. The stock is currently down 22.6% year-to-date, down 73.2% over the past 12 months, and down 79.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 16.0% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 647.9% The company's stock price performance over the past 12 months lags the peer average by 139.8%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
Neoleukin Therapeutics Inc Shares Fall 2.1% Below Previous 52-Week Low - Market Mover
02:51am, Thursday, 13'th Jan 2022 Kwhen Finance
Neoleukin Therapeutics Inc (NLTX) shares closed 2.1% lower than its previous 52 week low, giving the company a market cap of $163M. The stock is currently down 19.9% year-to-date, down 72.4% over the past 12 months, and down 77.8% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.6%. Trading Activity Trading volume this week was 46.6% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -3395.4% The company's stock price performance over the past 12 months lags the peer average by 152.2%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
Neoleukin Therapeutics Inc Shares Fall 2.5% Below Previous 52-Week Low - Market Mover
01:37am, Wednesday, 12'th Jan 2022 Kwhen Finance
Neoleukin Therapeutics Inc (NLTX) shares closed 2.5% lower than its previous 52 week low, giving the company a market cap of $178M. The stock is currently down 12.9% year-to-date, down 70.1% over the past 12 months, and down 76.7% over the past five years. This week, the Dow Jones Industrial Average fell 1.3%, and the S&P 500 fell 2.6%. Trading Activity Trading volume this week was 38.6% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 496.5% The company's stock price performance over the past 12 months lags the peer average by 131.7%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with KEYTRUDA® (pembrolizumab)
01:00pm, Monday, 10'th Jan 2022 GlobeNewswire Inc.
- NL-201 plus pembrolizumab to be evaluated in advanced solid tumor patients -- Combination testing anticipated to begin in 2022 -
Neoleukin Therapeutics Presenting at H.C. Wainwright BIOCONNECT Virtual Conference
11:00am, Monday, 10'th Jan 2022 GlobeNewswire Inc.
SEATTLE, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo
Neoleukin Therapeutics Presenting at H.C. Wainwright BIOCONNECT Virtual Conference
06:00am, Monday, 10'th Jan 2022
SEATTLE, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo pr
Neoleukin Therapeutics Inc Shares Fall 3.3% Below Previous 52-Week Low - Market Mover
02:57am, Saturday, 08'th Jan 2022 Kwhen Finance
Neoleukin Therapeutics Inc (NLTX) shares closed 3.3% lower than its previous 52 week low, giving the company a market cap of $181M. The stock is currently down 11.4% year-to-date, down 71.6% over the past 12 months, and down 75.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 22.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 10.7% lower than its 5-day moving average, 17.3% lower than its 20-day moving average, and 35.7% lower than its 90-day moving average.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 1261.8% The company's stock price performance over the past 12 months lags the peer average by 139.8%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
Neoleukin Therapeutics Inc Shares Close the Day 10.4% Higher - Daily Wrap
01:44am, Thursday, 23'rd Dec 2021 Kwhen Finance
Neoleukin Therapeutics Inc (NLTX) shares closed today 10.4% higher than it did at the end of yesterday. The stock is currently down 65.1% year-to-date, down 56.7% over the past 12 months, and down 67.6% over the past five years. Today, the Dow Jones Industrial Average rose 0.7%, and the S&P 500 rose 1.0%. Trading Activity Shares traded as high as $5.12 and as low as $4.64 this week.Shares closed 69.7% below its 52-week high and 18.0% above its 52-week low.Trading volume this week was 28.4% higher than the 10-day average and 7.0% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 122.8% The company's stock price performance over the past 12 months lags the peer average by 84.8%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021)
10:30pm, Saturday, 11'th Dec 2021 GlobeNewswire Inc.
– Poster presentation highlights NL-201 activity in multiple myeloma stem cell transplant model – – Abstract reports activity of NL-201 as monotherapy and anti-PD1 combination in non-Hodgkin l
Neoleukin Therapeutics to Present at Upcoming Investor Conferences
08:00am, Tuesday, 09'th Nov 2021
SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo pr
SEATTLE, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo pr
Neoleukin Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
08:00am, Tuesday, 07'th Sep 2021
SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo p